Apotex Strikes Licensing Deal To Settle Pennsaid IP Row

Law360, New York (January 29, 2013, 2:33 PM EST) -- Apotex Inc. has agreed to a licensing deal with Nuvo Research Inc. to end patent infringement litigation in Delaware over its plans to make a generic version of arthritis treatment cream Pennsaid, Nuvo said Tuesday.

The settlement allows Apotex to release its planned generic version of its 1.5 percent by weight generic diclofenac sodium cream 45 days after Nuvo or its U.S. licensee Mallinckrodt Inc. make a first commercial shipment of Pennsaid 2%, a new version of the drug containing 2 percent of the active ingredient,...
To view the full article, register now.